Nurix Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Beaurang Pierre | Chief Business Officer | Sale | 7,100 | $23.88 | $169,548 | 4,730 | Jul 12, 2021 |
| Hansen Gwenn | Chief Scientific Officer | Option Exercise | 400 | $7.26 | $2,904 | 14,204 | Jul 1, 2021 |
| Ring Christine | General Counsel | Sale | 1,000 | $29.18 | $29,180 | 1,005 | Jun 10, 2021 |
| Beaurang Pierre | Chief Business Officer | Sale | 400 | $30.90 | $12,360 | 4,330 | Jun 10, 2021 |
| Hansen Gwenn | Chief Scientific Officer | Sale | 400 | $27.74 | $11,096 | 13,804 | Jun 1, 2021 |
| Ring Christine | General Counsel | Option Exercise | 1,200 | $1.86 | $2,232 | 2,005 | May 10, 2021 |
| Beaurang Pierre | Chief Business Officer | Sale | 4,299 | $26.07 | $112,075 | 7,531 | May 10, 2021 |
| Third Rock Ventures GP III, L.P. | — | Other | 1,085,784 | — | — | 3,422,549 | May 6, 2021 |
| Svennilson Peter | — | Other | 10,307 | — | — | 10,307 | May 5, 2021 |
| Ponoi Management, LLC | — | Other | 10,307 | — | — | 10,307 | May 5, 2021 |
| Hansen Gwenn | Chief Scientific Officer | Sale | 800 | $35.00 | $28,000 | 13,804 | May 3, 2021 |
| Ring Christine | General Counsel | Option Exercise | 800 | $1.86 | $1,488 | 1,605 | Apr 28, 2021 |
| Ring Christine | General Counsel | Option Exercise | 1,200 | $1.86 | $2,232 | 2,005 | Apr 12, 2021 |
| Beaurang Pierre | Chief Business Officer | Sale | 4,072 | $26.83 | $109,252 | 7,758 | Apr 12, 2021 |
| Hansen Gwenn | Chief Scientific Officer | Option Exercise | 400 | $7.26 | $2,904 | 14,204 | Apr 5, 2021 |
| Hansen Gwenn | Chief Scientific Officer | Option Exercise | 400 | $7.26 | $2,904 | 14,204 | Apr 1, 2021 |
| Beaurang Pierre | Chief Business Officer | Option Exercise | 4,330 | $0.84 | $3,637 | 4,330 | Mar 25, 2021 |
| Hansen Gwenn | Chief Scientific Officer | Option Exercise | 800 | $7.26 | $5,808 | 14,604 | Mar 16, 2021 |
| Ring Christine | General Counsel | Sale | 395 | $44.11 | $17,423 | 805 | Mar 10, 2021 |
| Beaurang Pierre | Chief Business Officer | Sale | 200 | $38.34 | $7,668 | — | Mar 8, 2021 |
| Hansen Gwenn | Chief Scientific Officer | Option Exercise | 800 | $7.26 | $5,808 | 14,604 | Mar 1, 2021 |
| van Houte Hans | Chief Financial Officer | Sale | 35,419 | $39.90 | $1,413,218 | — | Feb 24, 2021 |
| van Houte Hans | Chief Financial Officer | Option Exercise | 1,417 | $0.84 | $1,190 | 1,417 | Feb 22, 2021 |
| van Houte Hans | Chief Financial Officer | Sale | 3,140 | $34.24 | $107,514 | 10,443 | Feb 18, 2021 |
| Ring Christine | General Counsel | Sale | 400 | $34.48 | $13,792 | 1,600 | Feb 18, 2021 |
| Hansen Gwenn | Chief Scientific Officer | Sale | 600 | $35.81 | $21,486 | 12,200 | Feb 18, 2021 |
| Beaurang Pierre | Chief Business Officer | Option Exercise | 9,107 | $0.84 | $7,650 | 9,107 | Feb 18, 2021 |
| Third Rock Ventures III, L.P. | — | Other | 914,216 | — | — | 4,508,333 | Feb 4, 2021 |
| Hansen Gwenn | Chief Scientific Officer | Option Exercise | 12,000 | $0.84 | $10,080 | 12,000 | Nov 30, 2020 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | — | C | 784,313 | — | — | 784,313 | Jul 28, 2020 |
| Green Jeremy | — | C | 1,176,470 | — | — | 1,176,470 | Jul 28, 2020 |
| COLUMN GROUP L P | — | C | 600,000 | — | — | 683,333 | Jul 28, 2020 |
| Ponoi II Management, LLC | — | C | 875,000 | — | — | 1,558,333 | Jul 28, 2020 |
| LEVIN MARK J | — | C | 39,216 | — | — | 5,422,549 | Jul 28, 2020 |
| Tjian Robert | — | C | 50,000 | — | — | 124,999 | Jul 28, 2020 |